For a health plan, an inaccurate medication list is not a documentation problem happening somewhere else. It flows directly into the three things a payer measures itself by: what it spends, how it scores on quality, and whether its members trust it. A list that doesn’t reflect what the patient is actually taking degrades all three.
Here is how medication list accuracy reaches the payer’s balance sheet, its Star Rating, and its reputation with members.
The spend: nonadherence and preventable events the plan pays for
The single most common discrepancy patients surface is a medication they have stopped taking — the exact signal a plan needs to see and usually can’t (Gionfriddo et al., JMIR Form Res 2022). When that signal is missing, the downstream cost lands on the payer.
- Medication nonadherence is associated with roughly $100–$300 billion in avoidable US healthcare costs annually and up to 25% of hospitalizations (Iuga & McGuire, Risk Manag Healthc Policy 2014; AJMC 2026).
- The majority of that cost is avoidable hospitalization — the most expensive place for a medication problem to surface (PMC3934668).
- Preventable ADEs from injectable medications alone are estimated to raise annual US payer costs by $2.7–$5.1 billion, averaging about $600,000 per hospital (National Burden of Preventable ADEs, PMC4031698).
- Nonadherant patients have significantly higher hospital admission and ED rates than adherent ones — the utilization a plan most wants to prevent (Acare HCP).
A plan cannot manage adherence it cannot see. When the record says a member is on a statin they quietly stopped in March, every adherence intervention built on that record is aimed at the wrong target.
The score: Star Ratings are built on medication data
For Medicare Advantage plans, medication accuracy isn’t just a cost input — it’s a rated quality measure with direct revenue consequences.
- Three Part D adherence measures — for diabetes medications, RAS antagonists, and statins — are each triple-weighted, and together determine roughly one-third of a plan’s overall Star Rating (Health Affairs Forefront).
- Star Ratings carry large financial implications, determining quality bonus payments and rebates that plans reinvest in benefits and member acquisition (J Manag Care Spec Pharm 2025).
- In a study of 103,900 Medicare Advantage members, adherence to these quality measures was associated with 21%–50% reductions in inpatient stays and ED visits and 11%–13% lower total healthcare costs (Bacci et al., AJMC 2024).
- Thresholds are tightening: compared with 2022, there was a 35% decrease in plans achieving 4 stars or better — raising the stakes on every measurable input (AnewHealth 2025).
Adherence measures are calculated from proportion of days covered — dispensing data. But a plan that can distinguish a true non-fill from a member who filled elsewhere, or who was correctly deprescribed, targets its outreach far more precisely. A medication picture that reflects what the member is actually taking is the raw material of a defensible Star performance.
The approval process: bad medication data slows and denies
Prior authorization is where the payer and the medication list meet most directly — and where inaccurate data creates friction on both sides.
- A leading cause of prior-authorization denial is incomplete or inaccurate clinical and medication information, including undocumented prior medication trials required for step therapy — which forces resubmission and appeal (Tebra 2026; DataMatrix 2026).
- 27% of physicians report that drug prior-authorization requirement information in their EHR is rarely or never accurate, and 63% find it difficult even to determine whether a medication needs authorization (AMA 2026).
- When documentation is corrected and standardized, denials fall sharply — one group cut MRI-related denials 72% and turnaround from 10 days to 3 by ensuring prior medication trials and outside data were captured (DataMatrix 2026).
Every avoidable denial and resubmission is administrative cost for the plan and delayed therapy for the member. An accurate, patient-confirmed medication picture upstream of the authorization is the cheapest way to reduce the volume of authorizations that fail on bad inputs.
The trust: members judge the plan by the friction they feel
Member trust is not a soft metric for a plan competing on Star Ratings and retention. It erodes precisely where medication data fails.
Physicians report that 88% of the time prior authorization interferes with continuity of care, and 61% say it at least sometimes destabilizes a previously stable patient (AMA 2026). From the member’s chair, a denied or delayed medication reads as the plan’s failure — regardless of where the inaccurate data originated. And the CAHPS and complaint measures that feed Star Ratings capture exactly that experience, so member frustration loops back into the plan’s rated quality.
The member doesn’t distinguish between the clinic’s list, the pharmacy’s fills, and the plan’s claims. They experience one thing: whether the system knew what they were taking. When it doesn’t, the plan wears the friction.
Why no single feed closes the gap for the payer
The payer’s structural disadvantage is that claims see only what was billed. Nearly half of US patients use multiple pharmacies, and dispensing-based adherence scores can’t follow a member across them — so a missing fill may mean the member stopped, or simply filled elsewhere (Open Forum Infect Dis 2023). Adherence estimated from dispensing alone came out at 42% versus 56% from claims — and for multiple-pharmacy users, 35% versus 67% (PMC8990834). No claims feed detects an OTC, a supplement, or the medication a member stopped without telling anyone.
The one party who sees the whole picture — every prescriber, every pharmacy, the OTCs, and the quiet discontinuations — is the member. A plan that finds a low-friction way to let members confirm what they’re actually taking is closing the exact blind spot its claims data can’t.
ConfirmMyMeds is a working application built at the clinic level, where the confirmation happens before the visit and the clinician decides what enters the record. It is not a payer product today, and it has no outcome data — we won’t claim it improves adherence scores, reduces denials, or raises Star Ratings, because we haven’t measured any of that. What the evidence above establishes is only where the blind spot is. We’re looking for design partners to help us learn whether asking the patient first actually narrows it.